Additional Condition for Nonprescription Use
FDA's 2024 final rule creating a pathway for nonprescription drug products that rely on additional conditions (e.g., self-selection tools, drug-device combinations) to ensure safe use without a healthcare provider.
Definition
An Additional Condition for Nonprescription Use (ACNU) is a labeling or implementation condition, beyond conventional Drug Facts labeling, that FDA may require for a nonprescription drug product to assure consumers can self-select and self-use the product safely. ACNUs may include digital self-assessment apps, device-mediated questionnaires, response-based vending, or other technological gating mechanisms. The final rule (Dec 2024) creates an explicit regulatory framework for products that would otherwise be unable to switch from Rx to OTC because labeling alone cannot ensure safe use.What this means in practice
ACNU is highly relevant to drug-device combination products and digital therapeutics that act as the 'additional condition' enabling safe OTC use. Examples include app-mediated screening for hormonal contraceptives, device-confirmed glucose checks for OTC insulin pens, or AI-assisted symptom triage gating access to a Rx-to-OTC switch. Manufacturers building these conditions must meet medical device requirements (often as a SaMD) in parallel with the drug NDA/ANDA pathway.- •Treating an ACNU app as marketing software, it is part of the labeling and likely a regulated medical device.
- •Failing to integrate human factors testing of the ACNU early, FDA expects evidence the additional condition actually achieves safe self-selection.
- •Ignoring post-market obligations, manufacturers must monitor whether the ACNU continues to function as intended in real-world use.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsProduct comprised of two or more regulated components - e.g., drug-device, biologic-device.
All written, printed, or graphic matter on or accompanying a device.
Software-based interventions that prevent, manage, or treat disease.
Engineering discipline focused on safe and effective device use by intended users.
More in Regulatory
· Same categoryFDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.
Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.
510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.
Primary references
3 sources- 1
FDA ACNU Final Rule (Dec 2024)VerifiedFederal Registerfederalregister.gov
- 2
FDA ACNU Web PageVerifiedFDAfda.gov
- 3
European Commission - Medical DevicesVerifiedEuropean Commissionhealth.ec.europa.eu
Inline markers like [1] jump to the matching reference above.